Latest Hotspot

Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event

19 June 2024
3 min read

Kymera Therapeutics, Inc., a biopharmaceutical company in the clinical stage that focuses on developing a novel category of small molecule drugs via targeted protein degradation, revealed new clinical data from its ongoing Phase 1 trial of KT-333. KT-333, a pioneering and powerful heterobifunctional small molecule degrader specifically targeting STAT3, showed antitumor activity in hematological cancers with significant unmet needs, such as relapsed/refractory classic Hodgkin's lymphoma, cutaneous T-cell lymphoma, and NK-cell lymphoma, at well-tolerated dosage levels.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

"The complete responses observed in Hodgkin’s lymphoma highlight the transformative therapeutic potential of STAT3 degradation," stated Jared Gollob, MD, Chief Medical Officer at Kymera Therapeutics. "Within the KT-333 trial, two extensively pretreated cHL patients transitioned to potentially curative stem cell transplants post-treatment. 

The ongoing Phase 1 trial continues to provide encouraging data, demonstrating the clinical translation of our degrader's profile across various hematological malignancies, including cHL, CTCL, and NK-cell lymphoma, potentially bettering patients' lives. We anticipate completing the dose escalation phase and sharing the comprehensive dataset later this year."

The Phase 1 KT-333 clinical trial is assessing the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of KT-333 administered weekly in 28-day cycles to adult patients with relapsed and/or refractory lymphomas, leukemias, and solid tumors.

In cHL, complete responses were achieved in two out of three patients at DL4. These responders, previously treated with at least one regimen including a checkpoint inhibitor and brentuximab vedotin, subsequently underwent stem cell transplantation. Additionally, stable disease was recorded in another cHL patient at DL6.

For NK-cell lymphoma, one patient with a STAT3 mutation achieved a complete response at DL7. Among nine CTCL patients, partial responses were seen in four patients at DL2 and DL4-6, with stable disease in one patient at DL4.

Furthermore, induction of an IFN-γ stimulated gene signature, predictive of anti-PD1 sensitivity, was detected in both peripheral blood and tumor, suggesting a favorable immunomodulatory response in the tumor microenvironment post-KT-333 treatment. This supports potential novel combinations with anti-PD1 drugs in solid tumors.

KT-333 was generally well tolerated, with most adverse events being Grade 1 and 2, including stomatitis and fatigue. Dose-limiting toxicities of Grade 3 stomatitis and arthralgia occurred in LGL-L patients at DL5, and Grade 3 fatigue was observed in a lymphoma patient at DL7."

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 19, 2024, there are 128 investigational drugs for the STAT3 targets, including 139 indications, 117 R&D institutions involved, with related clinical trials reaching 128, and as many as 11264 patents.

Lirodegimod shows promise as a potential treatment for a variety of serious and rare diseases, and its Fast Track and Orphan Drug designations indicate that it may address unmet medical needs in these therapeutic areas. As the drug progresses through clinical development, further research and testing will be necessary to determine its safety and efficacy for the indicated conditions.

图形用户界面, 文本, 应用程序, 网站

描述已自动生成

Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
Latest Hotspot
3 min read
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
19 June 2024
Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.
Read →
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
Latest Hotspot
3 min read
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
18 June 2024
FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.
Read →
Research Progress on GPCR Antibody Drugs
Hot Spotlight
18 min read
Research Progress on GPCR Antibody Drugs
18 June 2024
Aimovig™ (erenumab) is an injectable human monoclonal antibody (mAb) co-developed and co-marketed by Novartis and Amgen, indicated for the preventive treatment of migraines in adults.
Read →
Celltrion Shows Promising Phase III Results for RA Biosimilar CT-P47 at EULAR 2024
Latest Hotspot
3 min read
Celltrion Shows Promising Phase III Results for RA Biosimilar CT-P47 at EULAR 2024
18 June 2024
Celltrion presents encouraging phase III data for CT-P47, a biosimilar of RoActemra® (tocilizumab), in RA patients at EULAR 2024.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.